AJOVista LLC Invests $68,000 in Accolade, Inc. (NASDAQ:ACCD)

AJOVista LLC bought a new position in Accolade, Inc. (NASDAQ:ACCD) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 5,645 shares of the company’s stock, valued at approximately $68,000.

A number of other large investors have also made changes to their positions in ACCD. BluePath Capital Management LLC bought a new position in shares of Accolade during the 3rd quarter worth approximately $28,000. DekaBank Deutsche Girozentrale bought a new stake in Accolade in the third quarter valued at approximately $28,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Accolade by 84.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,928 shares of the company’s stock valued at $126,000 after purchasing an additional 5,455 shares during the last quarter. Olympiad Research LP bought a new position in shares of Accolade in the third quarter valued at about $171,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Accolade by 39.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,584 shares of the company’s stock worth $199,000 after buying an additional 4,656 shares during the last quarter. Institutional investors own 84.99% of the company’s stock.

Accolade Stock Performance

ACCD traded up $0.28 during midday trading on Friday, hitting $7.54. The company had a trading volume of 677,665 shares, compared to its average volume of 778,971. Accolade, Inc. has a 52 week low of $6.33 and a 52 week high of $15.36. The company has a current ratio of 2.64, a quick ratio of 2.35 and a debt-to-equity ratio of 0.47. The stock’s 50 day moving average price is $9.30 and its 200 day moving average price is $9.93.

Accolade (NASDAQ:ACCD) last posted its quarterly earnings results on Thursday, April 25th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $124.80 million during the quarter, compared to the consensus estimate of $123.91 million. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.53%. The business’s revenue was up 26.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.42) earnings per share. As a group, analysts predict that Accolade, Inc. will post -1.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Accolade in a report on Tuesday, January 9th. Leerink Partnrs reissued an “outperform” rating on shares of Accolade in a report on Monday, February 26th. Morgan Stanley dropped their target price on shares of Accolade from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Truist Financial dropped their price objective on shares of Accolade from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Finally, Raymond James boosted their target price on shares of Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Accolade currently has an average rating of “Moderate Buy” and a consensus target price of $14.57.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.